SCHEMBL374396

SCHEMBL374396

NC(=O)C1(C(=O)N(c2ccc(F)cc2)c2ccc(Oc3ccnc4cc(O)ccc34)c(F)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.46
AXL P30530 12/20 0.46
KDR P35968 4/20 0.46
MERTK Q12866 7/20 0.44
RET P07949 3/20 0.40
KIT P10721 3/20 0.40
FLT3 P36888 3/20 0.40
PDGFRA P16234 1/20 0.40
HDAC2 Q92769 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
PDGFRB P09619 1/20 0.39
AURKA O14965 1/20 0.39
RIPK2 O43353 1/20 0.39
ABCB11 O95342 1/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
NTRK1 P04629 1/20 0.39
LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377027 0.94 MET (0.40) METAXLKDRMERTK
SCHEMBL29453858 0.90 MET (0.46) METAXLKDRMERTKRET
SCHEMBL22749958 0.90 MET (0.46) METAXLKDRMERTKRET
SCHEMBL411533 0.90 MET (0.46) METAXLKDRMERTKRET
SCHEMBL28676521 0.88 AXL (0.49) METAXLKDRMERTKRET
SCHEMBL31412944 0.87 MET (0.62) METAXLKDRMERTKRET
SCHEMBL408158 0.87 MET (0.62) METAXLKDRMERTKRET
SCHEMBL374207 0.86 AXL (0.55) METAXLKDRMERTKRET
SCHEMBL31412940 0.86 AXL (0.55) METAXLKDRMERTKRET
SCHEMBL372297 0.86 AXL (0.55) METAXLKDRMERTKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408300-B1 AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE SUNSHINE LAKE PHARMA CO LTD (CN) 2016-05-11 EP disclosed
US-8232294-B2 Amino ester derivatives, sailts thereof and methods of use Xi, Ning (US) 2012-07-31 US disclosed
EP-2408300-A1 AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE Sunshine Lake Pharma Co., Ltd (CN) 2012-01-25 EP disclosed
WO-2010111063-A1 AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE XI NING (US) 2010-09-30 WO disclosed
US-20100239576-A1 AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239576-A1 AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE SRC, BCAT1, BCAT2 MET 185/4885AXL 373/4885KDR 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.